A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.

• Main Authors: Ermias Diro (Author), Severine Blesson (Author), Tansy Edwards (Author), Koert Ritmeijer (Author), Helina Fikre (Author), Henok Admassu (Author), Aderajew Kibret (Author), Sally J Ellis (Author), Clelia Bardonneau (Author), Eduard E Zijlstra (Author), Peninah Soipei (Author), Brian Mutinda (Author), Raymond Omollo (Author), Robert Kimutai (Author), Gabriel Omwalo (Author), Monique Wasunna (Author), Fentahun Tadesse (Author), Fabiana Alves (Author), Nathalie Strub-Wourgaft (Author), Asrat Hailu (Author), Neal Alexander (Author), Jorge Alvar (Author)
• 格式: 圖書
• 出版: Public Library of Science (PLoS), 2019-01-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

<h4>Background</h4>Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a low...